학술논문
Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Document Type
Article
Author
Source
Subject
*DRUG therapy
*MYELOID leukemia
*STEM cells
*TRANSPLANTATION of organs, tissues, etc.
*
*
*
Language
ISSN
0268-3369
Abstract
Studies the incidence of hepatic veno-occlusive disease of gemtuzumab ozogamicin monotherapy and its efficacy for relaped acute myeloid leukaemia after hematopoietic stem cell transplant. Methodology; Results of the study; Discussion of findings.